

Date: 09-09-2025

European Medicines Agency  
Domenico Scarlattilaan 6  
1083 HS Amsterdam  
The Netherlands

**Subject: Withdrawal of initial marketing authorisation application of  
Equidormin, 5 mg/ml solution for injection for horses,  
EMA/V/C/0006593**

Dear Madam, dear Sir,

I would like to inform you that, at this point of time, CP-Pharma Handelsgesellschaft has taken the decision to withdraw the application for Marketing Authorisation of Equidormin, 5 mg/ml solution for injection for horses.

This withdrawal is based on a commercial decision.

Due to invalidation of granted LMA status and with this change of legal basis of the application the investment needed to address the questions raised by the CVMP during the assessment of the MA application is considerable in relation to possible outcome of the procedure.

We reserve the right to make further Marketing Authorisation Application submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely,

